Serologic Evidence for Hepatitis B Virus Infection in Patients with Hemophilia B^[*]

Summary

Among sera from 160 patients with hemophilia B from 9 centers in Europe and North and South America, 2.5% were positive for hepatitis B surface antigen (HB_sAg), 60% for antibody to HB_sAg, and 31% for antibody to the hepatitis B core antigen. Evidence of exposure to the hepatitis B virus appeared to be related to severity of disease and age rather than the source and method of manufacturer of factor IX concentrate.

^* Task Force Report

• References

• 1 Barker L. F, Hoofnagle J. H. Transmission of viral hepatitis, type B, by plasma derivatives. 13th International Congress of IABS Budapest. . 1973
• 2 Boklan B. F. Factor IX concentrate and viral hepatitis. Annals of Internal Medicine 1971; 74: 298
• 3 Gocke D. J, Howe C. Rapid detection of Australia antigen by counterelectrophoresis. Journal of Immunology 1970; 104: 1031
• 4 Hoofnagle J. H, Gerety R. J, Barker L. F. Antibody to hepatitis B virus core in man. Lancet 1973; ii: 869
• 5 Kasper C. K, Kipnis S. A. Hepatitis and clotting-factor concentrates. Journal of the American Medical Association 1972; 221: 510
• 6 Ling C. M, Overby L. R. Prevalence of hepatitis B virus antigen as revealed by direct radioimmune assay with 125-I antibody. Journal of Immunology 1972; 109: 834
• 7 Prince A. M, Brotman B, Jass D, Ikram M. Specificity of the direct solid-phase radioimmunoassay for the detection of hepatitis-B-antigen. Lancet i: 1346 1973;
• 8 Vyas G. N, Shulman N. R. Hemagglutination assay for antigen and antibody associated with viral hepatitis. Science 1970; 170: 332